王潔，1965年生，中國醫(yī)科院腫瘤醫(yī)院內(nèi)科主任，主任醫(yī)師，北京協(xié)和醫(yī)學(xué)院長聘教授。中國臨床腫瘤學(xué)會(huì)副理事長，中國醫(yī)師協(xié)會(huì)腫瘤多學(xué)科專委會(huì)主任委員。近30年來致力于肺癌分子分型基礎(chǔ)上精準(zhǔn)診治及轉(zhuǎn)化研究工作。主持國自然基金重點(diǎn)項(xiàng)目、科技部專項(xiàng)等20余項(xiàng)。國家自然科學(xué)基金委杰出青年基金獲得者，以第一完成人獲得國家科技進(jìn)步二等獎(jiǎng)，獲全國創(chuàng)新爭(zhēng)先獎(jiǎng)、何梁何利基金科學(xué)技術(shù)與進(jìn)步獎(jiǎng)、吳階平醫(yī)藥創(chuàng)新獎(jiǎng)、中國青年女科學(xué)家獎(jiǎng)、教育部創(chuàng)新團(tuán)隊(duì)帶頭人等。

肺癌、胸膜間皮瘤、胸腺腫瘤的精準(zhǔn)診治；肺癌分子分型、免疫分型的轉(zhuǎn)化和臨床研究。

久久综合九色欧美综合狠狠_伊人热热久久原色播放WWW_成A人片亚洲日本久久_久久不见久久见免费影院www日本_97久久精品人人做人人爽,又色又爽又黄的视频在线观看,狼群影院视频在线观看高清版,亚洲AV无码精品网站性色,国产乱码久久久久久红粉影视,精品国产乱码久久久久久一区二区,国产精品免费视频网站,国产A级毛片久久久久久精品,一级特黄高清aaaa大片,亚洲中文字幕欧美一区,久久精品国产99久久狂热,黑人巨大精品欧美_黑人巨大精品欧美黑寡妇_黑人巨大精品欧美一区二区_黑人巨大精品欧美一区二区免费_黑人巨大跨种族video_黑人巨大无码中文字幕无码_黑人巨茎大战俄罗斯美女_黑人巨茎大战俄罗斯美女,中文字幕av不卡|亚洲欧美国产另类|天天干在线播放|日韩黄视频|欧美七区|可以免费看毛片的网站|黄色片在线|国产精品96久久久久久

<fieldset id="cgs4q"></fieldset>

1. Jie Wang#, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Chengping Hu, Wenhua Zhao, Ben Zhang, Wei Shi, Xiaojing Zhang, Ying Cheng. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Jun;23(6): 739-747. (IF=54.4)

2. Jiachen Xu, Zheng Liu, Hua Bai, Guilan Dong, Jia Zhong, Rui Wan, Aiming Zang, Xiaoling Li, Qingshan Li, Jun Guo, Nan Du, Diansheng Zhong, Yan Huang, Qun Lv, Jinghua Zhang, Yue Zhao, Liming Gao, Lin Li, Chunyi Zhang, Jun Zhao, Baolan Li, Zhe Liu, Zhenlin Yang, Dong Ji, Tao Wang, Jianchun Duan, Zhijie Wang, Jie Wang*. Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2022 Jul 21. (IF=33.0)

3. Jie Wang*, Shun Lu, Xinmin Yu, Yanping Hu, Yuping Sun, Zhijie Wang, Jun Zhao, Yan Yu, Chunhong Hu, Kunyu Yang, Guosheng Feng, Kejing Ying, Wu Zhuang, Jianying Zhou, Jingxun Wu, Shiang Jiin Leaw, Jing Zhang, Xiao Lin, Liang Liang, Nong Yang. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5): 709-717. (IF=33.0, ESI)

4. Jianchun Duan, Longgang Cui, Xiaochen Zhao, Hua Bai, Shangli Cai, Guoqiang Wang, Zhengyi Zhao, Jing Zhao, Shiqing Chen, Jia Song, Chuang Qi,  Qing Wang, Mengli Huang, Yuzi Zhang, Depei Huang, Yuezong Bai, Feng Sun, J Jack Lee, Zhijie Wang, Jie Wang*. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6:375-84. (IF 31.7)

5. Jiefei Han, Jianchun Duan, Hua Bai, Yuqi Wang, Rui Wan, Xin Wang, Si Chen,Yanhua Tian, Di Wang, Kailun Fei, Zhuoran Yao, Shuhang Wang, Zhimin Lu, ZhijieWang, Jie Wang*, TCR Repertoire Diversity of Peripheral PD-1(+)CD8(+) T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020 Jan;8(1):146-154. (IF 12.0, ESI)

6. Zhijie Wang, Jianchun Duan, Shangli Cai, Miao Han, Hua Dong, Jun Zhao, Bo Zhu, Shuhang Wang, Minglei Zhuo, Jiangguo Sun, Qiming Wang, Hua Bai, Jiefei Han, Yanhua Tian, Jing Lu, Tongfu Xu, Xiaochen Zhao, Guoqiang Wang, Xinkai Cao, Fugen Li, Dalei Wang, Yuejun Chen, Yuezong Bai, Jing Zhao, Zhengyi Zhao, Yuzi Zhang, Lei Xiong, Jie He, Shugeng Gao, Jie Wang* .Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncol. 2019 May 1;5(5):696-702. (IF 31.7,C100,ESI)

7. Zhijie Wang, Ying Cheng, Tongtong An, Hongjun Gao, Kai Wang, Qing Zhou, Yanping Hu, Yong Song, Cuimin Ding, Feng Peng, Li Liang, Yi Hu, Cheng Huang, Caicun Zhou, Yuankai Shi, Li Zhang, Xin Ye, Meizhuo Zhang, Shaokun Chuai, Guanshan Zhu, Jin Hu,Yi-long Wu, Jie Wang*. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma(BENEFIT): a phase 2, single-arm multicentre clinicla trial. Lancet Respir Med. 2018 Sep;6(9):681-690.   (IF=23.0)

8. Xiaohui Ni, Minglei Zhuo, Zhe Su, Jianchun Duan, Yan Gao, Zhijie Wang, Chenghang Zong, Hua Bai,Alec R. Chapman, Jun Zhao, Liya Xu, Tongtong An, Qi Ma, Yuyan Wang, Meina Wu, Yu Sun, Shuhang Wang, Zhenxiang Li, Xiaodan Yang, Jun Yong, XiaoDong Su, Youyong Lu, Fan Bai, X. Sunney Xie, Jie Wang*. Reproducible Copy Number Variation Patterns among Single Circulating Tumor Cells of Lung Cancer Patients. Proc Natl Acad Sci USA. 2013 Dec 24; 110(52): 21083-8. (IF=11.2, ESI)

9. Hua Bai, Zhijie Wang, Keneng Chen, Jun Zhao, J. Jack Lee, Shuhang Wang, Qinghua Zhou, Minglei Zhuo, Li Mao, Tongtong An, Jianchun Duan, Lu Yang, Meina Wu, Zhen Liang, Yuyan Wang, Xiaozheng Kang, Jie Wang*. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol. 2012 Sep 1;30(25):3077-83. (IF=17.9, C100)

10. Hua Bai, Li Mao, Shuhang Wang, Jun Zhao, Lu Yang, Tongtong An, Xin Wang, Jianchun Duan Meina Wu, Qingzhi Guo, Xuyi Liu, Ninghong Liu, Yuye Wang, Jie Wang*. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 2009 Jun 1;27(16):2653-9. (IF=16.9，C100)